MICB and acute myeloid leukemia: NKG2D has a broad specificity for ligands such as MHC class I polypeptide-related sequences A and B (MICA and MICB) and six members of the UL16-binding glycoproteins 1–6 (ULBP1–6) that are expressed on the surface of AML blasts in about 67–100% of AML cases, which makes CAR cells expressing NKG2D a potent AML killer [82].